Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol
Open Access
- 1 November 2008
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 155 (6) , 896-905
Abstract
Background and purpose: Genistein aglycone positively affects bone loss in postmenopausal women, but bone quality data are still lacking. To clarify this, we investigated the effects of genistein compared with alendronate, raloxifene and oestradiol in an animal model of established osteoporosis.Experimental approach: Six months after ovariectomy, 96 ovariectomized (OVX) rats were divided into 8 equal groups, randomized to treatments (genistein aglycone (1 and 10 mg kg−1 s.c.); alendronate (0.003 and 0.03 mg kg−1 s.c.); raloxifene hydrochloride (0.05 and 0.5 mg kg−1 s.c.); 17‐α‐ethinyl oestradiol (0.003 and 0.03 mg kg−1 s.c.)) for 12 weeks. Untreated OVX (n=12) and sham OVX (n=12) were used as controls. At the beginning and end of treatment, bone mineral density (BMD) and bone mineral content (BMC) were assessed. At the end of the experiment, calcium, phosphorus, bone‐alkaline phosphatase (b‐ALP), collagen C‐telopeptide (CTX), osteoprotegerin (OPG) and soluble receptor activator of nuclear factor‐κB ligand (sRANKL) were assayed. Femurs were removed and tested for breaking strength and histology.Key results: Genistein (10 mg kg−1) showed a greater increase in both BMD (PPBritish Journal of Pharmacology (2008) 155, 896–905; doi:10.1038/bjp.2008.305; published online 11 August 2008Keywords
This publication has 57 references indexed in Scilit:
- Mechanisms of Anabolic Therapies for OsteoporosisNew England Journal of Medicine, 2007
- Isoflavones made simple – Genistein’s agonist activity for the beta-type estrogen receptor mediates their health benefitsMedical Hypotheses, 2006
- Expression Profiling of Rat Femur Revealed Suppression of Bone Formation Genes by Treatment with Alendronate and Estrogen but Not RaloxifeneMolecular Pharmacology, 2005
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Purified phytoestrogens in postmenopausal bone health: is there a role for genistein?Climacteric, 2002
- Purified phytoestrogens in postmenopausal bone health: is there a role for genistein?Climacteric, 2002
- Difference in Effective Dosage of Genistein on Bone and Uterus in Ovariectomized MiceBiochemical and Biophysical Research Communications, 2000
- Suppressive Effect of Genistein on Rat Bone Osteoclasts: Apoptosis Is Induced through Ca2+ Signaling.Biological and Pharmaceutical Bulletin, 1999
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997